Perjeta: new option for HER2-positive breast cancer

Perjeta (pertuzumab) is licensed for HER2-positive metastatic or locally recurrent unresectable breast cancer in patients who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease, in combination with trastuzumab and docetaxel.

Perjeta (pertuzumab) and Herceptin (trastuzumab) used together produce a more comprehensive blockade of HER2 signalling and thus greater antitumour activity than either agent used alone
Perjeta (pertuzumab) and Herceptin (trastuzumab) used together produce a more comprehensive blockade of HER2 signalling and thus greater antitumour activity than either agent used alone

PHARMACOLOGY 

Pertuzumab, a monoclonal antibody, targets the extracellular dimerization domain of the human epidermal growth factor 2 (HER2) protein but at a different subdomain to trastuzumab. It inhibits ligand-initated intracellular signalling, resulting in cell growth arrest and apoptosis.1

CLINICAL STUDIES

Pertuzumab was investigated in the pivotal randomised, double-blind, placebo-controlled phase III trial CLEOPATRA in 808 patients with HER2-positive metastatic or locally recurrent unresectable breast cancer.1,2

Patients given pertuzumab, in combination with trastuzumab and docetaxel, had a median progression-free survival of 18.5 months compared with 12.4 months for those in the placebo arm (HR=0.62, 95% CI 0.52–0.75; p<0.0001).2

The most common adverse reactions reported were diarrhoea, alopecia and neutropenia.1,2

 REFERENCES

  1. Perjeta Summary of Product Characteristics, March 2013
  2. Baselga J et al. N Engl J Med 2012; 366: 109-19.

View Perjeta drug record

Further information: Roche

Follow MIMS on Twitter


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.